Clinical Phases of AKI Therapeutics Treatment
| Treatment | Discovery | Preclinical | Clinical Phases |
|---|---|---|---|
| AKI-051 Acute kidney injury |
|
||
Achievements of the preclinical phase
Indication of target
Study of causes and pathology of AKI to identify new treatment strategies. Completed in 2015.
Identification of API
Review and identification of candidate active substances. Completed 2015-2016.
Identification of carrier
Review and identification of candidate targeting carrier molecules/proteins. Completed in 2016-2017.
Identification of linking procedure for API and carrier
Prioritisation of active substances and targeting carrier proteins. Identification of linking strategies. Completed in 2018-2019.
Phase 1 of the preclinical phase
- Production of recombinant modified mouse API and synthesis of preferred active substance to the linker arm.
- Synthesis of preferred active substance via the linker arm to API.
- Testing of cell and tissue uptake.
Completed in 2020-2022
Phase 2 of the preclinical phase
- Testing efficacy of the active conjugate in mouse models of AKI.
- Toxicity studies in pre-clinical models.
Testing efficacy of the conjugate in in-vivo mouse models are ongoing.
